1. Home
  2. Clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients with advanced nonesmall-cell lung cancer in a retrospective multicenter trial.

Clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients with advanced nonesmall-cell lung cancer in a retrospective multicenter trial.

Clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients
with advanced nonesmall-cell lung cancer in a retrospective multicenter
trial.

Nonadenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS). PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events;
however, PFS and OS were shorter in patients with interstitial lung disease


    Customer Area

    Make your order right away

    Confidentiality and privacy guaranteed

    satisfaction guaranteed

@ 2019 Brilliant Essay Help